Company: DRTSW
Filing Date: 2025-06-23
Form Type: F-3
Source: 0001213900-25-056744
Chunk: 2

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-06-23
Form: F-3
Chunk 2
---
us relates to
the resale by the selling shareholders named in this prospectus (the “Selling Shareholders”) from time to time of up to an
aggregate of 3,463,202 ordinary shares, no par value per share (the “ordinary shares”) in amounts, at prices and on terms
that will be determined at the time of any such offering. The ordinary shares being registered for resale hereunder comprise (i) 3,237,000
ordinary shares issuable upon the exercise of the IR/PR Warrants (as defined below) that were acquired by Oramed Ltd. (“Oramed”)
pursuant to a Strategic Services Agreement (as defined below) and (ii) 226,202 ordinary shares that were acquired by A & M Construction
Co., Inc. (“A & M Construction”) as consideration for an amendment to a Design-Build Agreement (as defined below, together
with the Strategic Services Agreement, the “Agreements”). We are registering the ordinary shares for resale pursuant to the
terms of the Agreements.

Our ordinary shares are listed
on the Nasdaq Stock Market LLC under the trading symbol “DRTS.” On June 20, 2025, the closing price for our ordinary shares
on the Nasdaq Stock Market LLC was $2.90 per ordinary share.

We will not receive any of
the proceeds from the sale of the ordinary shares by the Selling Shareholders; however, we expect to receive approximately $12.26 million
from the exercise of the IR/PR Warrants, assuming such IR/PR Warrants were exercised in full, unless such IR/PR Warrants were exercised
on a “cashless” basis. The ordinary shares issuable upon the exercise of the IR/PR Warrants will have been issued by us following
such exercise and prior to any resale of such shares pursuant to this prospectus.

The Selling Shareholders
named in this prospectus and any of their pledgees, assignees and successors-in-interest, may offer or resell the ordinary shares from
time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately
negotiated prices. The Selling Shareholders will bear all commissions and discounts, if any, attributable to the sale of the ordinary
shares. We will bear all costs, expenses and fees associated with the registration of the securities covered by this prospectus, as described
in the section entitled “Plan of Distribution.”

For additional
information